TOP RATED 2013

RealRate

PHARMACEUTICAL 2013

Abbott Laboratories
Rank 25 of 218

Abbott



TOP RATED 2013

RealRate

PHARMACEUTICAL 2013

Abbott Laboratories
Rank 25 of 218

Abbott

The relative strengths and weaknesses of Abbott Laboratories are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Abbott Laboratories compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 94% points.The greatest weakness of Abbott Laboratories is the variable Other Expenses, reducing the Economic Capital Ratio by 8.8% points.

The company's Economic Capital Ratio, given in the ranking table, is 373%, being 152% points above the market average of 220%.

Input Variable	Value in 1000 USD
Assets, Current	31,322,583
Cost of Goods Sold	0
Intangible Assets	24,362,412
Liabilities, Current	13,280,176
Liabilities, Non-Current	0
Other Assets	3,486,902
Other Compr. Net Income	-996,493
Other Expenses	16,011,815
Other Liabilities	0
Other Net Income	-1,229,498
Other Revenues	39,873,910
Property and Equipment	8,063,047
Research and Development	4,610,182
Selling, General and Administrative Expense	12,059,495

Output Variable	Value in 1000 USD
Assets	67,234,944
Liabilities	13,280,176
Expenses	32,681,492
Revenues	39,873,910
Stockholders Equity	53,954,768
Net Income	5,962,920
Comprehensive Net Income	5,464,674
BaseVar	77,648,256
ECR before LimitedLiability	306%
Economic Capital Ratio	373%